Louisiana's First Gene Therapy Cure for Sickle Cell Disease
On June 24 2026, a milestone in genetic medicine was celebrated in Louisiana when 23‑year‑old Daniel Cressy was declared functionally cured of sickle cell disease after undergoing experimental gene therapy at Manning Family Children’s Hospital in New Orleans. Sickle cell disease, a hereditary disorder that distorts red blood cells into a sickle shape, has long plagued thousands of patients with painful crises, chronic organ damage, and reduced life expectancy.
The therapy, a cutting‑edge application of CRISPR/Cas9 gene editing, involved harvesting Cressy’s own hematopoietic stem cells, editing the DNA to correct the defective hemoglobin gene, and then re‑infusing the corrected cells after a brief chemotherapy regimen to clear existing diseased cells. Dr. Zachary LeBlanc, a pediatric hematologist‑oncologist at the hospital, explained that the edited cells act as a “drug” produced by the body itself, restoring normal blood cell function without the need for ongoing transfusions or medication.
The procedure required two years of preparation, including a trip to Scotland where the cells were genetically modified, and a month of intensive monitoring after the infusion. Upon discharge, Cressy rang a ceremonial bell in the hospital’s Center for Cancer and Blood Disorders, joining mayor Helena Moreno, U.S. Representative Troy Carter, and Governor Jeff Landry in celebrating what they called a “proud and transformational moment.”
Beyond the personal triumph, the success signals a broader shift in the treatment of hemoglobin disorders. Only a few hundred patients worldwide have received curative gene therapy for sickle cell disease, and most have been treated in Europe or on the East Coast. Cressy’s case demonstrates that the technology can be safely administered in the Gulf Coast, a region with one of the highest per‑capita rates of sickle cell disease in the United States.
Motivated by his own experience, Cressy co‑founded the nonprofit Privileged Pilots, which aims to increase awareness, provide support to families navigating treatment, and advocate for equitable access to cutting‑edge therapies regardless of zip code. He hopes the story will inspire other patients and encourage insurers, policymakers, and research institutions to invest in broader availability of gene‑editing cures.
The breakthrough also underscores the importance of continued funding for rare‑disease research. While the therapy costs millions per patient, its potential to eliminate lifelong medical expenses and improve quality of life could yield substantial long‑term savings for the healthcare system.
As the medical community watches this development, the hope is that more patients across the nation will benefit from similar curative options, turning a once‑fatal genetic condition into a treatable, if not reversible, disease.
